Shilpa Medicare announces positive Phase 3 results for Oeris
OERIS offers extended antiemetic coverage through a single injection that effectively prevents both acute and delayed CINV for up to five days
OERIS offers extended antiemetic coverage through a single injection that effectively prevents both acute and delayed CINV for up to five days
The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Sprycel Tablets
RedHill has obtained a court-approved asset attachment in South Korea to prevent Kukbo from transferring or disposing of assets ahead of enforcement of the judgment
During the quarter, Zydus Wellness completed the acquisition of Comfort Click Limited and its subsidiaries
The antibody was designed and developed at Abzena’s Cambridge, UK,
Medherant’s testosterone TEPI Patch could become the first-in-class testosterone patch developed specifically for women
The acquisition centers on ImCheck’s lead Phase I/II program, ICT01, a first-in-class monoclonal antibody targeting BTN3A
Medroxyprogesterone acetate-SC is a three-month contraceptive that can be administered by healthcare workers or self-injected after appropriate training
Indegene is strengthening its Consulting Practice to help life sciences organizations address their most pressing challenges with speed, impact, and accountability
Subscribe To Our Newsletter & Stay Updated